Business In Brief
This article was originally published in The Tan Sheet
Executive Summary
Pfizer: Consumer Healthcare sales of $741 mil., up 14%, in the second quarter, were driven by the continued strong performance of Listerine mouthwash and uptake of Listerine PocketPaks in international markets. The rollout of FreshBurst Listerine line extensions and the weaker dollar also helped edge up revenues. Sales of PocketPaks in the U.S. slowed and the firm's Benadryl and Sudafed line were hurt by the presence of OTC Claritin on the market, Pfizer notes...
You may also be interested in...
Martek acquisition
Columbia, Md.-based firm completes purchase of FermPro Manufacturing and its Kingstree, S.C. plant. Transaction is expected to add at least $30 to $50 mil. of production capacity for Martek after operations and equipment are fully integrated (1"The Tan Sheet" July 28, 2003, p. 14). Martek also is in the process of spending $20 mil. to $30 mil. to increase manufacturing capacity of its Winchester, Ky. facility (2"The Tan Sheet" June 9, 2003, p. 9). Firm appoints FermPro President & CEO Barney Easterling as Martek VP...
Martek Production Capacity Expected To Reach $200 Mil.-$250 Mil. in 2004
Martek plans to spend between $20 mil. and $30 mil. over the next 12 months on increasing its fermentation capacity, the Columbia, Md.-based firm said during a June 3 analysts call
Weight-Loss Segment Future Uncertain With PPA Actions, Ephedra Questions
FDA actions discouraging the use of phenylpropanolamine-containing products will further accelerate the recent shift away from the OTC appetite suppressant ingredient toward ephedra supplements.